Given the variability in the hypothesized epidemiological factors affecting the frequency and distribution of BRAF mutations in NSCLC, molecular testing through next-generation sequencing (NGS) provides the best prognostic tool for their identification [78]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.